Evidence map›Paper›PMID 28176893›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2017

Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.

Jadwiga A Wedzicha, Nanshan Zhong, Masakazu Ichinose, Michael Humphries, Robert Fogel, Chau Thach, Francesco Patalano, Donald Banerji

Open access · goldAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 5 countries.

Jadwiga A WedzichaNational Heart and Lung Institute, Imperial College London, London, UK.
Nanshan ZhongState Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
Masakazu IchinoseDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Michael HumphriesBeijing Novartis Pharma Co. Ltd., Shanghai, People's Republic of China.
Robert FogelNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Chau ThachNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Francesco PatalanoNovartis Pharma AG, Basel, Switzerland.
Donald BanerjiNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Novartis (United States) · USImperial College London · GBNovartis (China) · CNNovartis (Switzerland) · CHState Key Laboratory of Respiratory Disease · CNTohoku University · JP

Funding

Medical Research Council G0800570Medical Research Council G1001365Medical Research Council G1001372
6 · The paper itself

Abstract

backgroundThe FLAME study demonstrated that indacaterol/glycopyrronium (IND/GLY), the fixed-dose combination of a long-acting β PATIENTS AND

methodsPatients from Asian centers with moderate-to-very severe COPD and ≥1 exacerbation in the previous year from the 52-week, randomized FLAME study were included. IND/GLY was compared versus SFC for effects on exacerbations, lung function (forced expiratory volume in 1 second [FEV

resultsA total of 510 Asian patients (IND/GLY, n=250 or SFC, n=260) were included. Compared to the overall FLAME population, the Asian cohort had more males, a shorter duration of COPD, fewer patients using inhaled corticosteroid (ICS) at screening, fewer current smokers, and more patients with very severe COPD. IND/GLY significantly reduced the rate of moderate/severe exacerbations (rate ratio: 0.75; 95% confidence interval: 0.58-0.97;

conclusionIn exacerbating Asian COPD patients, IND/GLY was more effective than SFC.

Indexed as

Asian PeopleAdrenergic beta-2 Receptor AgonistsAgedAsiaBronchodilator AgentsDisease ProgressionDouble-Blind MethodFemaleFluticasone-Salmeterol Drug CombinationForced Expiratory VolumeGlycopyrrolateHealth StatusHumansIndansLungMaleAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsFluticasone-Salmeterol Drug CombinationGlycopyrrolateindacaterolIndansMuscarinic AntagonistsQuinolonesAsiabronchodilator agentschronic obstructive pulmonary diseaseexacerbationsindacaterol/glycopyrronium

Identifiers

PMID28176893
PMCPMC5261570
OpenAlexW2579315308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.